Vigeo Therapeutics
Cambridge
About Vigeo Therapeutics
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies. The company was established in 2011 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Mar 2021)
- Website: vigeotherapeutics.com
- Phone: 617-945-0385
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vigeo-therapeutics-22614 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.